Quingestanol acetate

Quingestanol acetate
Clinical data

Routes of administration	Oral
ATC code	G03AC04 (WHO) G03AA02 (WHO) (with an estrogen)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (17β)-3-(Cyclopentyloxy)-17-ethynylestra-3,5-dien-17-yl acetate
Synonyms	W-4540
CAS Number	3000-39-3
PubChem CID	18142
ChemSpider	17136
ECHA InfoCard	100.019.163
Chemical and physical data
Formula	C₂₇H₃₆O₃
Molar mass	408.573 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(O[C@@]5(C#C)CC[C@@H]4[C@]5(C)CC[C@@H]3[C@@H]2C(\C=C(\OC1CCCC1)CC2)=C/C[C@H]34)C
InChI InChI=1S/C27H36O3/c1-4-27(30-18(2)28)16-14-25-24-11-9-19-17-21(29-20-7-5-6-8-20)10-12-22(19)23(24)13-15-26(25,27)3/h1,9,17,20,22-25H,5-8,10-16H2,2-3H3/t22-,23+,24+,25-,26-,27-/m0/s1 Key:FLGJKPPXEKYCBY-AKCFYGDASA-N

Quingestanol acetate (INN, USAN) (brand names Demovis, Pilomin, Riglovis, Unovis), also known as norethisterone acetate 3-cyclopentyl enol ether, is a steroidal progestin of the 19-nortestosterone group with additional weak androgenic and estrogenic activity which is used as an oral, once-a-month, or postcoital hormonal contraceptive. It is a prodrug of norethisterone, with both quingestanol and norethisterone acetate serving as intermediates in the transformation. The drug was patented in 1963 and marketed in Italy in 1972.